SNYNF:OTC-Sanofi (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 114.5

Change

0.00 (0.00)%

Market Cap

USD 142.76B

Volume

2.30K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 258.74B
RHHVF Roche Holding AG Participation

-6.28 (-2.05%)

USD 258.74B
RHHBF Roche Holding AG

N/A

USD 258.74B
AZNCF AstraZeneca PLC

-0.14 (-0.09%)

USD 241.92B
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.12 (-0.51%)

USD 83.22B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 63.77B
ALPMF Astellas Pharma Inc

N/A

USD 21.46B
ALPMY Astellas Pharma Inc

N/A

USD 21.25B
RICFY Recordati Industria Chimica e ..

N/A

USD 11.87B
KYKOF Kyowa Kirin Co. Ltd

N/A

USD 11.02B

ETFs Containing SNYNF

SEUC:PA SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

N/A

USD 1.16B
SYBD:F SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

-0.02 (-0.07%)

USD 1.16B
SYBD:XETRA SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

-0.02 (-0.07%)

USD 1.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.95% 73% C 67% D+
Dividend Return 4.09% 89% A- 59% D-
Total Return 19.03% 76% C+ 69% C-
Trailing 12 Months  
Capital Gain 8.56% 55% F 58% F
Dividend Return 3.86% 84% B 52% F
Total Return 12.42% 59% D- 59% D-
Trailing 5 Years  
Capital Gain 28.38% 74% C 72% C
Dividend Return 21.03% 83% B 65% D
Total Return 49.40% 71% C- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 1.19% N/A N/A 41% F
Dividend Return 4.93% N/A N/A 43% F
Total Return 3.74% N/A N/A 63% D
Risk Return Profile  
Volatility (Standard Deviation) 11.61% N/A N/A 95% A
Risk Adjusted Return 42.42% N/A N/A 79% B-
Market Capitalization 142.76B 80% B- 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector